HLA-C and cancer: While conventional mAbs bind the same antigen with both fragment antigen-binding (Fab) arms [47], BTCEs simultaneously bind a TAA on cancer cells and the epsilon (ε) subunit of CD3 on the T lymphocytes and, therefore, can efficiently trigger redirected T-cell cytotoxicity in an MHC-independent fashion [48,49].